Diabetes and obesity
Continuous glucose monitoring improved blood sugar control in adults with type 2 diabetes
In the 283-person CONNECT trial, CGM lowered mean HbA1c more than routine care by week 26 in adults with type 2 diabetes not using insulin.
MedPage Today reported that the randomized CONNECT trial found continuous glucose monitoring (CGM) reduced HbA1c in adults with type 2 diabetes who were not treated with insulin. Among 283 patients at 22 U.S. primary care practices, mean HbA1c fell from 8.8% to 7.2% in the CGM group and from 8.7% to 8.0% with routine care by week 26. Time in the target glucose range, 70-180 mg/dL, was 21 percentage points higher with CGM, equivalent to about 5 more hours per day.
The trial also found that time spent in severe hyperglycemia was 15 percentage points lower with CGM. No cases of severe hypoglycemia or hyperglycemia-related serious adverse events were observed. Median CGM use was 97% of the time, though the researchers said trial support and visit frequency may have affected adherence. A 26-week extension is underway to assess sustained use and whether the effects last.
